Buzz: Will Brent Saun­ders split up Al­ler­gan if he los­es the Resta­sis patent fight?

With its stock trad­ing south of $200 af­ter the big Resta­sis set­back on the patent front, you can hear the grow­ing buzz of an­a­lysts ea­ger­ly spec­u­lat­ing about the chance that Al­ler­gan $AGN may soon be forced to break up the com­pa­ny to de­liv­er for in­vestors.

As you may have heard, a fed­er­al judge re­cent­ly in­val­i­dat­ed the Resta­sis patents for ob­vi­ous­ness, the kind of slap down that has a high like­li­hood of stand­ing up un­der ap­peal. So with its $1.5 bil­lion fran­chise ther­a­py tee­ter­ing on the brink, it’s easy to see how hiv­ing off Al­ler­gan’s sta­ble and prof­itable aes­thet­ics busi­ness — built around Botox — could work in its fa­vor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.